Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection
Open accessThe DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
Clostridium difficile epidemiology has changed in recent years, with the emergence of highly virulent types associated with severe infections, high rates of recurrences and mortality. Antibiotic resistance plays an important role in driving these epidemiological changes and the emergence of new types. While clindamycin resistance was driving historical endemic types, new types are associated with resistance to fluoroquinolones. Furthermore, resistance to multiple antibiotics is a common feature of the newly emergent strains and, in general, of many epidemic isolates. A reduced susceptibility to antibiotics used for C. difficile infection (CDI) treatment, in particular to metronidazole, has recently been described in several studies. Furthermore, an increased number of strains show resistance to rifamycins, used for the treatment of relapsing CDI. Several mechanisms of resistance have been identified in C. difficile, including acquisition of genetic elements and alterations of the antibiotic target sites. The C. difficile genome contains a plethora of mobile genetic elements, many of them involved in antibiotic resistance. Transfer of genetic elements among C. difficile strains or between C. difficile and other bacterial species can occur through different mechanisms that facilitate their spread. Investigations of the fitness cost in C. difficile indicate that both genetic elements and mutations in the molecular targets of antibiotics can be maintained regardless of the burden imposed on fitness, suggesting that resistances may persist in the C. difficile population also in absence of antibiotic selective pressure. The rapid evolution of antibiotic resistance and its composite nature complicate strategies in the treatment and prevention of CDI. The rapid identification of new phenotypic and genotypic traits, the implementation of effective antimicrobial stewardship and infection control programs, and the development of alternative therapies are needed to prevent and contain the spread of resistance and to ensure an efficacious therapy for CDI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Clostridium difficile infection in Europe: a hospital-based survey
Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., & Kuijper, E. J. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61266-4 · Cited by 1,020
The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome
Sebaihia, M., Wren, B. W., Mullany, P., Fairweather, N. F., Minton, N., Stabler, R., Thomson, N. R., Roberts, A. P., Cerdeño-Tárraga, A. M., Wang, H., et al. (2006) · Nature Genetics · doi:10.1038/ng1830 · Cited by 879
The Changing Epidemiology of Clostridium difficile Infections
Freeman, J., Bauer, M. P., Baines, S. D., Corver, J., Fawley, W. N., Goorhuis, B., Kuijper, E. J., & Wilcox, M. H. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00082-09 · Cited by 826
Emergence and global spread of epidemic healthcare-associated Clostridium difficile
He, M., Miyajima, F., Roberts, P., Ellison, L., Pickard, D. J., Martin, M. J., Connor, T. R., Harris, S. R., Fairley, D., Bamford, K. B., et al. (2013) · Nature Genetics · doi:10.1038/ng.2478 · Cited by 735
Risk factors for Clostridium difficile infection
Bignardi, G. E. (1998) · Journal of Hospital Infection · doi:10.1016/s0195-6701(98)90019-6 · Cited by 647
Muto, C. A., Pokrywka, M., Shutt, K., Mendelsohn, A. B., Nouri, K., Posey, K., Roberts, T., Croyle, K., Krystoflak, S., Patel-Brown, S., et al. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502539 · Cited by 619
Pepin, J. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050978 · Cited by 606
Slimings, C., & Riley, T. V. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt477 · Cited by 581
Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C. (2005) · Clinical Infectious Diseases · doi:10.1086/430315 · Cited by 570
Burden of Clostridium difficile on the Healthcare System
Dubberke, E. R., & Olsen, M. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis335 · Cited by 557
Relatively Poor Outcome after Treatment of Clostridium difficile Colitis with Metronidazole
Musher, D. M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F., & Hamill, R. J. (2005) · Clinical Infectious Diseases · doi:10.1086/430311 · Cited by 504
Clindamycin-Associated Colitis Due to a Toxin-Producing Species of Clostridium in Hamsters
Bartlett, J. G., Onderdonk, A. B., Cisneros, R. L., & Kasper, D. L. (1977) · Journal of Infectious Diseases · doi:10.1093/infdis/136.5.701 · Cited by 472
Wistrom, J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.1.43 · Cited by 448
Current Status of Clostridium difficile Infection Epidemiology
Lessa, F. C., Gould, C. V., & McDonald, L. C. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis319 · Cited by 439
Increase in Clostridium difficile–related Mortality Rates, United States, 1999–2004
Redelings, M. D., Sorvillo, F., & Mascola, L. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1309.061116 · Cited by 429
Johnson, S., Samore, M. H., Farrow, K. A., Killgore, G. E., Tenover, F. C., Lyras, D., Rood, J. I., DeGirolami, P., Baltch, A. L., Rafferty, M. E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911253412203 · Cited by 379
Evolutionary dynamics of Clostridium difficile over short and long time scales
He, M., Sebaihia, M., Lawley, T. D., Stabler, R. A., Dawson, L. F., Martin, M. J., Holt, K. E., Seth-Smith, H. M. B., Quail, M. A., Rance, R., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914322107 · Cited by 359
Miller, B. A., Chen, L. F., Sexton, D. J., & Anderson, D. J. (2011) · Infection Control & Hospital Epidemiology · doi:10.1086/659156 · Cited by 350
Kim, J., Smathers, S. A., Prasad, P., Leckerman, K. H., Coffin, S., & Zaoutis, T. (2008) · Pediatrics · doi:10.1542/peds.2008-0469 · Cited by 321
Bolton, R. P., & Culshaw, M. A. (1986) · Gut · doi:10.1136/gut.27.10.1169 · Cited by 320
Louie, T. J., Cannon, K., Byrne, B., Emery, J., Ward, L., Eyben, M., & Krulicki, W. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis338 · Cited by 310
Multiple Factors Modulate Biofilm Formation by the Anaerobic Pathogen Clostridium difficile
Thapa, T., Leuzzi, R., Ng, Y. K., Baban, S. T., Adamo, R., Kuehne, S. A., Scarselli, M., Minton, N. P., Serruto, D., & Unnikrishnan, M. (2013) · Journal of Bacteriology · doi:10.1128/jb.01980-12 · Cited by 291
Freeman, J., Vernon, J., Morris, K., Nicholson, S., Todhunter, S., Longshaw, C., & Wilcox, M. H. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.09.017 · Cited by 279
Keel, K., Brazier, J. S., Post, K. W., Weese, S., & Songer, J. G. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00224-07 · Cited by 266
Vardakas, K. Z., Polyzos, K. A., Patouni, K., Rafailidis, P. I., Samonis, G., & Falagas, M. E. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.01.004 · Cited by 250
Emergence of reduced susceptibility to metronidazole in Clostridium difficile
Baines, S. D., O'Connor, R., Freeman, J., Fawley, W. N., Harmanus, C., Mastrantonio, P., Kuijper, E. J., & Wilcox, M. H. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn313 · Cited by 247
Gravel, D., Miller, M., Simor, A., Taylor, G., Gardam, M., McGeer, A., Hutchinson, J., Moore, D., Kelly, S., Boyd, D., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596703 · Cited by 243
Roberts, A. P., & Mullany, P. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00283.x · Cited by 242
Muto, C. A., Blank, M. K., Marsh, J. W., Vergis, E. N., O'Leary, M. M., Shutt, K. A., Pasculle, A. W., Pokrywka, M., Garcia, J. G., Posey, K., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/522654 · Cited by 241
Macrocyclic Drugs and Synthetic Methodologies toward Macrocycles
Yu, X., & Sun, D. (2013) · Molecules · doi:10.3390/molecules18066230 · Cited by 231
Tannock, G. W., Munro, K., Taylor, C., Lawley, B., Young, W., Byrne, B., Emery, J., & Louie, T. (2010) · Microbiology · doi:10.1099/mic.0.042010-0 · Cited by 217
Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread
Clements, A. C., Magalhães, R. J. S., Tatem, A. J., Paterson, D. L., & Riley, T. V. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70080-3 · Cited by 206
Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile
O'Connor, J. R., Galang, M. A., Sambol, S. P., Hecht, D. W., Vedantam, G., Gerding, D. N., & Johnson, S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00342-08 · Cited by 187
Evolutionary History of the Clostridium difficile Pathogenicity Locus
Dingle, K. E., Elliott, B., Robinson, E., Griffiths, D., Eyre, D. W., Stoesser, N., Vaughan, A., Golubchik, T., Fawley, W. N., Wilcox, M. H., et al. (2014) · Genome Biology and Evolution · doi:10.1093/gbe/evt204 · Cited by 185
Multidrug resistance in European Clostridium difficile clinical isolates
Spigaglia, P., Barbanti, F., Mastrantonio, P., on behalf of the European Study Group on Clostridium difficile (ESGCD), Ackermann, G., Balmelli, C., Barbut, F., Bouza, E., Brazier, J., Delmee, M., et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr292 · Cited by 183
Self-citationGerding, D. N. (2004) · Clinical Infectious Diseases · doi:10.1086/382084 · Cited by 175
New target for inhibition of bacterial RNA polymerase: ‘switch region’
Srivastava, A., Talaue, M., Liu, S., Degen, D., Ebright, R. Y., Sineva, E., Chakraborty, A., Druzhinin, S. Y., Chatterjee, S., Mukhopadhyay, J., et al. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.030 · Cited by 172
Young, G. P., Ward, P. B., Bayley, N., Gordon, D., Higgins, G., Trapani, J. A., McDonald, M. I., Labrooy, J., & Hecker, R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90206-9 · Cited by 171
Antimicrobial resistance in Clostridium difficile
Huang, H., Weintraub, A., Fang, H., & Nord, C. E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.012 · Cited by 169
Goorhuis, A., Van der Kooi, T., Vaessen, N., Dekker, F. W., Van den Berg, R., Harmanus, C., van den Hof, S., Notermans, D. W., & Kuijper, E. J. (2007) · Clinical Infectious Diseases · doi:10.1086/520984 · Cited by 159
Heteroresistance: a concern of increasing clinical significance?
Falagas, M. E., Makris, G. C., Dimopoulos, G., & Matthaiou, D. K. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01912.x · Cited by 159
Metronidazole Resistance in Clostridium difficile Is Heterogeneous
Peláez, T., Cercenado, E., Alcalá, L., Marín, M., Martín-López, A., Martínez-Alarcón, J., Catalán, P., Sánchez-Somolinos, M., & Bouza, E. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00524-08 · Cited by 157
Curry, S. R., Marsh, J. W., Shutt, K. A., Muto, C. A., O’Leary, M. M., Saul, M. I., Pasculle, A. W., & Harrison, L. H. (2009) · Clinical Infectious Diseases · doi:10.1086/596315 · Cited by 157
The emergence of ‘hypervirulence’ in Clostridium difficile
Cartman, S. T., Heap, J., Kuehne, S. A., Cockayne, A., & Minton, N. P. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2010.04.008 · Cited by 138
Clostridium difficile PCR Ribotype 078: an Emerging Strain in Humans and in Pigs?
Goorhuis, A., Debast, S. B., van Leengoed, L. A. M. G., Harmanus, C., Notermans, D. W., Bergwerff, A. A., & Kuijper, E. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01536-07 · Cited by 130
Johnson, S., Schriever, C. A., Patel, U. C., Patel, T. C., Hecht, D. W., & Gerding, D. N. (2009) · Anaerobe · doi:10.1016/j.anaerobe.2009.08.004 · Cited by 122
Mullany, P. P., Wilks, M., Lamb, I., Clayton, C. L., Wren, B. W., & Tabaqchali, S. (1990) · Journal of General Microbiology · doi:10.1099/00221287-136-7-1343 · Cited by 122
Goh, S., Hussain, H. A., Chang, B. J., Emmett, W., Riley, T. V., & Mullany, P. P. (2013) · mBio · doi:10.1128/mbio.00840-13 · Cited by 121
Dridi, L., Tankovic, J., Burghoffer, B., Barbut, F., & Petit, J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3418-3421.2002 · Cited by 117
Spigaglia, P., & Mastrantonio, P. (2004) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45682-0 · Cited by 107
Self-citationEmergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage
Valiente, E., Dawson, L. F., Cairns, M. D., Stabler, R. A., & Wren, B. W. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.036194-0 · Cited by 104
Khan, R., & Cheesbrough, J. (2003) · Journal of Hospital Infection · doi:10.1016/s0195-6701(03)00115-4 · Cited by 100
THE CHEMICAL BASIS FOR THE ACTION OF THE VANCOMYCIN GROUP OF ANTIBIOTICS
Perkins, H. R., & Nieto, M. (1974) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1974.tb43276.x · Cited by 99
Farrow, K. A., Lyras, D., & Rood, J. I. (2001) · Microbiology · doi:10.1099/00221287-147-10-2717 · Cited by 98
Roberts, A. P., Johanesen, P., Lyras, D., Mullany, P. P., & Rood, J. I. (2001) · Microbiology · doi:10.1099/00221287-147-5-1243 · Cited by 97
Clostridium difficile Toxinotype V, Ribotype 078, in Animals and Humans
Rupnik, M., Widmer, A., Zimmermann, O., Eckert, C., & Barbut, F. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00598-08 · Cited by 97
Brouwer, M. S. M., Warburton, P. J., Roberts, A. P., Mullany, P., & Allan, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023014 · Cited by 97
Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents
Jarrad, A. M., Karoli, T., Blaskovich, M. A. T., Lyras, D., & Cooper, M. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5016846 · Cited by 97
Leeds, J. A., Sachdeva, M., Mullin, S., Barnes, S. W., & Ruzin, A. V. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt302 · Cited by 97
Drudy, D., Quinn, T., O’Mahony, R., Kyne, L., Gaora, P. Ó., & Fanning, S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl398 · Cited by 96
Clostridium difficileIsolates Resistant to Fluoroquinolones in Italy: Emergence of PCR Ribotype 018
Spigaglia, P., Barbanti, F., Dionisi, A. M., & Mastrantonio, P. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02482-09 · Cited by 93
Self-citationAntimicrobial Susceptibility of Clostridium Difficile Clinical Isolates in Iran
Goudarzi, M., Goudarzi, H., Alebouyeh, M., Rad, M. A., Mehr, F. S. S., Zali, M. R., & Aslani, M. M. (2013) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.5189 · Cited by 92
Oka, K., Osaki, T., Hanawa, T., Kurata, S., Okazaki, M., Manzoku, T., Takahashi, M., Tanaka, M., Taguchi, H., Watanabe, T., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05588-11 · Cited by 91
Rodríguez-Pardo, D., Almirante, B., Bartolomé, R. M., Pomar, V., Mirelis, B., Navarro, F., Soriano, A., Sorlí, L., Martínez-Montauti, J., Molins, M. T., et al. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.03352-12 · Cited by 90
Ambrose, N. S., Johnson, M., Burdon, D. W., & Keighley, M. R. B. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/15.3.319 · Cited by 89
Wide Diversity Of Clostridium Difficile Types At A Tertiary Referral Hospital
Samore, M. H., Bettin, K. M., DeGirolami, P. C., Clabots, C., Gerding, D. N., & Karchmer, A. W. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/170.3.615 · Cited by 88
Characterization of a Stable, Metronidazole-Resistant Clostridium difficile Clinical Isolate
Lynch, T., Chong, P. M., Zhang, J., Hizon, R., Du, T., Graham, M., Beniac, D. R., Booth, T. F., Kibsey, P., Miller, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053757 · Cited by 87
Sears, P. S., Crook, D. W., Louie, T., Miller, M. A., & Weiss, K. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis337 · Cited by 87
Clostridium difficile is no longer just a nosocomial infection or an infection of adults
Pituch, H. M. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(09)70016-0 · Cited by 85
Mobile genetic elements in Clostridium difficile and their role in genome function
Mullany, P. P., Allan, E., & Roberts, A. P. (2015) · Research in Microbiology · doi:10.1016/j.resmic.2014.12.005 · Cited by 83
Clostridium difficileSurveillance Trends, Saxony, Germany
Burckhardt, F., Friedrich, A., Beier, D., & Eckmanns, T. (2008) · Emerging infectious diseases · doi:10.3201/eid1404.071023 · Cited by 75
Eckert, C., Coignard, B., Hébert, M., Tarnaud, C., Tessier, C., Lemire, A., Burghoffer, B., Noel, D., & Barbut, F. (2013) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2013.01.004 · Cited by 72
Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
Chong, P. M., Lynch, T., McCorrister, S. J., Kibsey, P., Miller, M., Gravel, D., Westmacott, G., Mulvey, M. R., & (CNISP), T. C. N. I. S. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0082622 · Cited by 72
Vuotto, C., Moura, I. B., Barbanti, F., Donelli, G., & Spigaglia, P. (2015) · Pathogens and Disease · doi:10.1093/femspd/ftv114 · Cited by 69
Self-citationClinical update for the diagnosis and treatment ofClostridium difficileinfection
Oldfield, E. C. (2014) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v5.i1.1 · Cited by 68
Pirš, T., Avberšek, J., Zdovc, I., Krt, B., Andlovic, A., Lejko-Zupanc, T., Rupnik, M., & Ocepek, M. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.058875-0 · Cited by 66
The functional vanGCd cluster of C lostridium difficile does not confer vancomycin resistance
Ammam, F., Meziane‐Cherif, D., Mengin‐Lecreulx, D., Blanot, D., Patin, D., Boneca, I. G., Courvalin, P. M., Lambert, T., & Candela, T. (2013) · Molecular Microbiology · doi:10.1111/mmi.12299 · Cited by 66
Samore, M. H., Killgore, G., Johnson, S., Goodman, R., Shim, J. K., Venkataraman, L., Sambol, S. P., DeGirolami, P. C., Tenover, F. C., Arbeit, R. D., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514117 · Cited by 65
Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile
Schmidt, C., Löffler, B., & Ackermann, G. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.03.009 · Cited by 64
Clostridium difficile Strains from Community-Associated Infections
Limbago, B. M., Long, C., Thompson, A. D., Killgore, G., Hannett, G. E., Havill, N. L., Mickelson, S., Lathrop, S. L., Jones, T. F., Park, M. M., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00964-09 · Cited by 64
Hächler, H., Berger‐Bächi, B., & Kayser, F. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1039 · Cited by 64
Mullany, P. P., Wilks, M., & Tabaqchali, S. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/35.2.305 · Cited by 58
Jasni, A. S., Mullany, P. P., Hussain, H. A., & Roberts, A. P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00496-10 · Cited by 57
Clostridium difficile PCR Ribotype 018, a Successful Epidemic Genotype
Baldan, R., Trovato, A., Bianchini, V., Biancardi, A., Cichero, P., Mazzotti, M. F., Nizzero, P., Moro, M., Ossi, C. M., Scarpellini, P., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00533-15 · Cited by 52
Phenotypic and Genotypic Analysis of Clostridium difficile Isolates: a Single-Center Study
Zhou, Y., Burnham, C. D., Hink, T., Chen, L., Shaikh, N., Wollam, A., Sodergren, E. J., Weinstock, G. M., Tarr, P. I., & Dubberke, E. R. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02115-14 · Cited by 51
Peláez, T., Alcalá, L., Blanco, J. L., Álvarez‐Pérez, S., Marı́n, M., Martín, A., Catalán, P., Reigadas, E., García, M. E., & Bouza, E. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.05.009 · Cited by 51
Clostridium difficile in faeces from healthy dogs and dogs with diarrhea
Wetterwik, K.-J., Trowald‐Wigh, G., Fernström, L., & Krovacek, K. (2013) · Acta veterinaria Scandinavica · doi:10.1186/1751-0147-55-23 · Cited by 51
Tetracycline Resistance Gene tet (W) in the Pathogenic Bacterium Clostridium difficile
Spigaglia, P., Barbanti, F., & Mastrantonio, P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00957-07 · Cited by 51
Self-citationFry, P. R., Thakur, S., Abley, M. J., & Gebreyes, W. A. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06581-11 · Cited by 50
Distribution of the vanG-like gene cluster in Clostridium difficile clinical isolates
Ammam, F., Marvaud, J., & Lambert, T. (2012) · Canadian Journal of Microbiology · doi:10.1139/w2012-002 · Cited by 47
Spigaglia, P., Drigo, I., Barbanti, F., Mastrantonio, P., Bano, L., Bacchin, C., Puiatti, C., Tonon, E., Berto, G., & Agnoletti, F. (2014) · Anaerobe · doi:10.1016/j.anaerobe.2014.10.003 · Cited by 46
Self-citationSpigaglia, P., Barbanti, F., Louie, T., Barbut, F., & Mastrantonio, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01252-08 · Cited by 44
Self-citationCorver, J., Bakker, D., Brouwer, M. S. M., Harmanus, C., Hensgens, M. P. M., Roberts, A. P., Lipman, L. J. A., Kuijper, E. J., & van Leeuwen, H. C. (2012) · BMC Microbiology · doi:10.1186/1471-2180-12-130 · Cited by 43
Moura, I. B., Monot, M., Tani, C., Spigaglia, P., Barbanti, F., Norais, N., Dupuy, B., Bouza, E., & Mastrantonio, P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02350-14 · Cited by 43
Self-citationClostridium difficile Infection: Update on Diagnosis, Epidemiology, and Treatment Strategies
To, K. B., & Napolitano, L. M. (2014) · Surgical Infections · doi:10.1089/sur.2013.186 · Cited by 42
Characterization of the genetic basis of antibiotic resistance in Clostridium difficle
Roberts, M. C., McFarland, L. V., Mullany, P. P., & Mulligan, M. E. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.3.419 · Cited by 40
Wasels, F., Monot, M., Spigaglia, P., Barbanti, F., Ma, L., Bouchier, C., Dupuy, B., & Mastrantonio, P. (2014) · Microbial Drug Resistance · doi:10.1089/mdr.2014.0015 · Cited by 39
Self-citationBüchler, A., Rampini, S. K., Stelling, S., Ledergerber, B., Peter, S., Schweiger, A., Ruef, C., Zbinden, R., & Speck, R. F. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0607-z · Cited by 39
Miller, M. A., Blanchette, R., Spigaglia, P., Barbanti, F., & Mastrantonio, P. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05100-11 · Cited by 39
Self-citationSpigaglia, P., Barbanti, F., & Mastrantonio, P. (2007) · Microbial Drug Resistance · doi:10.1089/mdr.2007.723 · Cited by 38
Self-citationHuang, J. S., Jiang, Z., Garey, K. W., Lasco, T. M., & DuPont, H. L. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00548-13 · Cited by 37
Mullany, P. P., Williams, R. J., Langridge, G. C., Turner, D. J., Whalan, R. H., Clayton, C., Lawley, T. D., Hussain, H. A., McCurrie, K., Morden, N., et al. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.06193-11 · Cited by 37
Álvarez‐Pérez, S., Blanco, J. L., Martínez‐Nevado, E., Peláez, T., Harmanus, C., Kuijper, E. J., & García, M. E. (2014) · Veterinary Microbiology · doi:10.1016/j.vetmic.2013.12.018 · Cited by 37
Varshney, J., Very, K. J., Williams, J. L., Hegarty, J. P., Stewart, D. B., Lumadue, J., Venkitanarayanan, K., & Jayarao, B. M. (2014) · Foodborne Pathogens and Disease · doi:10.1089/fpd.2014.1790 · Cited by 36
Spigaglia, P. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl105 · Cited by 36
Self-citationObuch-Woszczatyński, P., Lachowicz, D., Schneider, A., Mól, A., Pawłowska, J., Ożdżeńska-Milke, E., Pruszczyk, P., Wultańska, D., Młynarczyk, G., Harmanus, C., et al. (2014) · Anaerobe · doi:10.1016/j.anaerobe.2014.04.007 · Cited by 35
Wren, B. W., Mullany, P. P., Clayton, C. L., & Tabaqchali, S. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.8.1213 · Cited by 35
Brouwer, M. S. M., Roberts, A. P., Mullany, P., & Allan, E. (2012) · Mobile Genetic Elements · doi:10.4161/mge.19297 · Cited by 34
Walkty, A. J., Boyd, D. A., Gravel, D., Hutchinson, J., McGeer, A., MOORE, D. L., Simor, A. E., Suh, K. N., Taylor, G. D., Miller, M. A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.12.002 · Cited by 33
Diagnostic testing for Clostridium difficile in Italian microbiological laboratories
Spigaglia, P., Barbanti, F., Morandi, M., Moro, M. L., & Mastrantonio, P. (2015) · Anaerobe · doi:10.1016/j.anaerobe.2015.11.002 · Cited by 33
Self-citationIn Vivo Selection of Rifamycin-Resistant Clostridium difficile during Rifaximin Therapy
Carman, R. J., Boone, J. H., Grover, H., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00974-12 · Cited by 32
Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
Mullane, K. M., & Chaparro-Rojas (2013) · Infection and Drug Resistance · doi:10.2147/idr.s24434 · Cited by 30
Richardson, C., Kim, P., Lee, C., Bersenas, A. M. E., & Weese, J. S. (2015) · Anaerobe · doi:10.1016/j.anaerobe.2015.03.003 · Cited by 23
Ratnayake, L., McEwen, J., Henderson, N., Nathwani, D., Phillips, G., Brown, D., & Coia, J. E. (2011) · Journal of Hospital Infection · doi:10.1016/j.jhin.2011.06.013 · Cited by 20
Pecavar, V., Blaschitz, M., Hufnagl, P., et al. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.041087-0 · Cited by 18
Aogáin, M. M., Kilkenny, S., Walsh, C., Lindsay, S., Moloney, G., Morris, T., Jones, S. C. P., & Rogers, T. R. (2015) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2015.09.007 · Cited by 15
Cited by
Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches
Jubeh, B., Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25122888 · Cited by 383
Dingle, K. E., Didelot, X., Quan, T. P., Eyre, D. W., Stoesser, N., Golubchik, T., Harding, R. M., Wilson, D. J., Griffiths, D., Vaughan, A., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30514-x · Cited by 328
Epidemiology of antimicrobial resistance in bloodstream infections
Akova, M. (2016) · Virulence · doi:10.1080/21505594.2016.1159366 · Cited by 292
Bacteria from Animals as a Pool of Antimicrobial Resistance Genes
Argudín, M., Deplano, A., Meghraoui, A., Dodémont, M., Heinrichs, A., Denis, O., Nonhoff, C., & Roisin, S. (2017) · Antibiotics · doi:10.3390/antibiotics6020012 · Cited by 283
Peng, Z., Jin, D., Kim, H. B., Stratton, C. W., Wu, B., Tang, Y.-W., & Sun, X. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.02250-16 · Cited by 259
Metadata
- Authors
- Spigaglia, P.
- Venue
- Therapeutic Advances in Infectious Disease
- Publisher
- SAGE Publications
- Published
- 2015-12-23
- Volume
- 3
- Issue
- 1
- Pages
- 23-42
- ISSN
- 2049-9361 (ISSN-L)
- 2049-937X
- OpenAlex
- W2258394935
- Cited by
- 254
- References
- 121
- FWCI
- 17.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.